Coya Therapeutics IncNASDAQ:COYA
- LAST PRICE6.5000
- TODAY'S CHANGE (%)0.4200 (6.9079%)
- Bid / Lots6.3600/ 2
- Ask / Lots6.9200/ 1
- Open / Previous Close6.2400 / 6.0800
- Day Range
- 52 Week Range
- Volume68,283
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | COYA |
|---|---|---|
| 09:32 ET | 100 | 6.24 |
| 09:37 ET | 500 | 6.3084 |
| 09:46 ET | 188 | 6.2674 |
| 09:48 ET | 300 | 6.13 |
| 09:50 ET | 100 | 6.25 |
| 10:04 ET | 1000 | 6.15 |
| 10:15 ET | 400 | 6.1999 |
| 10:18 ET | 1000 | 6.2371 |
| 10:20 ET | 1635 | 6.2 |
| 10:22 ET | 819 | 6.28 |
| 10:27 ET | 3304 | 6.2899 |
| 10:31 ET | 1450 | 6.39 |
| 10:33 ET | 1648 | 6.31 |
| 10:38 ET | 100 | 6.38 |
| 10:54 ET | 100 | 6.38 |
| 10:58 ET | 5833 | 6.58 |
| 11:02 ET | 100 | 6.44 |
| 11:03 ET | 100 | 6.44 |
| 11:05 ET | 5796 | 6.58 |
| 11:07 ET | 3821 | 6.54 |
| 11:09 ET | 1100 | 6.5201 |
| 11:12 ET | 900 | 6.5334 |
| 11:14 ET | 100 | 6.515 |
| 11:16 ET | 249 | 6.46 |
| 11:18 ET | 165 | 6.6283 |
| 11:20 ET | 300 | 6.46 |
| 11:21 ET | 1198 | 6.44 |
| 11:27 ET | 5218 | 6.5796 |
| 11:30 ET | 100 | 6.5595 |
| 11:32 ET | 100 | 6.485 |
| 11:36 ET | 400 | 6.4957 |
| 11:38 ET | 400 | 6.515 |
| 11:39 ET | 299 | 6.45 |
| 11:41 ET | 100 | 6.56 |
| 11:45 ET | 1300 | 6.65 |
| 11:50 ET | 200 | 6.6313 |
| 11:52 ET | 100 | 6.65 |
| 11:54 ET | 100 | 6.5596 |
| 11:56 ET | 100 | 6.5595 |
| 12:08 ET | 100 | 6.64 |
| 12:30 ET | 400 | 6.5325 |
| 12:55 ET | 100 | 6.5746 |
| 01:08 ET | 150 | 6.5909 |
| 01:09 ET | 1871 | 6.65 |
| 01:22 ET | 780 | 6.64 |
| 01:26 ET | 100 | 6.68 |
| 01:29 ET | 1613 | 6.55 |
| 01:40 ET | 100 | 6.7 |
| 01:42 ET | 100 | 6.635 |
| 01:49 ET | 144 | 6.6653 |
| 01:56 ET | 100 | 6.69 |
| 02:20 ET | 3200 | 6.5001 |
| 02:21 ET | 250 | 6.5001 |
| 02:23 ET | 100 | 6.5 |
| 02:50 ET | 100 | 6.5 |
| 02:56 ET | 100 | 6.5 |
| 02:57 ET | 310 | 6.4058 |
| 03:03 ET | 100 | 6.48 |
| 03:06 ET | 430 | 6.43 |
| 03:14 ET | 475 | 6.39 |
| 03:17 ET | 600 | 6.35 |
| 03:19 ET | 100 | 6.35 |
| 03:26 ET | 447 | 6.35 |
| 03:28 ET | 150 | 6.4357 |
| 03:30 ET | 1255 | 6.41 |
| 03:32 ET | 300 | 6.4129 |
| 03:33 ET | 200 | 6.4195 |
| 03:35 ET | 500 | 6.33 |
| 03:37 ET | 1557 | 6.3991 |
| 03:50 ET | 400 | 6.4442 |
| 03:53 ET | 100 | 6.51 |
| 03:57 ET | 662 | 6.53 |
| 04:00 ET | 956 | 6.5 |
Nov 19, 2024
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders, from 8:15AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:15AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 11, 2024
DJ Coya Therapeutics Price Target Maintained With a $18.00/Share by HC Wainwright & Co., from 7:09AM ET on Monday Nov 11, 2024 by Dow Jones
7:09AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 7, 2024
DJ Coya Therapeutics Is Maintained at Buy by Chardan Capital, from 9:28AM ET on Thursday Nov 07, 2024 by Dow Jones
9:28AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Press Release: Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 06, 2024 by Dow JonesCoya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Coya Therapeutics Inc | 101.6M | -9.4x | --- |
Adlai Nortye Ltd | 96.3M | -0.4x | --- |
Generation Bio Co | 88.2M | -0.6x | --- |
Assembly Biosciences Inc | 93.6M | -2.0x | --- |
Avalo Therapeutics Inc | 100.3M | -0.9x | --- |
Ikena Oncology Inc | 94.5M | -1.4x | --- |
Company Information
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
Contact Information
- Headquarters
- 5850 San Felipe St., Suite 500HOUSTON, TX, United States 77057
- Phone
- 650-739-3939
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Howard Berman
- President, Chief Medical Officer
- Fred Grossman
- Director
- Arun Swaminathan
- Chief Financial Officer, Chief Operating Officer
- David Snyder
- Independent Director
- Dov Goldstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $101.6M |
|---|---|
Revenue (TTM) | $9.6M |
Shares Outstanding | 16.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.69 |
Book Value | $2.47 |
P/E Ratio | -9.4x |
Price/Sales (TTM) | 10.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -118.84% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
